title: Cancer incidence in a cohort of infertile women.
abstract: Among 2,496 infertile Israeli women treated between 1964 and 1974, 143 cancer cases were observed as compared with 116.1 expected (standardized incidence ratio (SIR) = 1.2, 95% confidence interval (CI) 1.0-1.5) through 1991. Site-specific analysis revealed 12 ovarian cancers versus 7.2 expected (SIR = 1.6, 95% CI 0.8-2.9), 21 endometrial cancers versus 4.3 expected (SIR = 4.85, 95% CI 3.0-7.4), and 59 breast cancers versus 46.6 expected (SIR = 1.3, 95% CI 0.96-1.6). Sensitivity analysis revealed that confounding was unlikely to explain the raised risk of endometrial cancer, but nulliparity might explain the increased risk of ovarian cancer. The excess of endometrial cancer was prominent among patients with normal estrogen production but progesterone deficiency (SIR = 9.4, 95% CI 5.0-16.0). The risk for ovarian cancer was similar among the total groups of treated and untreated patients (SIR = 1.7 vs. 1.6). The standardized incidence ratio for endometrial cancer was higher among the treated group than the untreated group, although not significantly. Treatment with ovulation-inducing drugs does not appear to increase the risk for ovarian cancer, but its role cannot be completely excluded.
authors.affiliation: Department of Clinical Epidemiology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Modan
authors.forename: E
authors.initials: E
authors.lastname: Ron
authors.forename: L
authors.initials: L
authors.lastname: Lerner-Geva
authors.forename: T
authors.initials: T
authors.lastname: Blumstein
authors.forename: J
authors.initials: J
authors.lastname: Menczer
authors.forename: J
authors.initials: J
authors.lastname: Rabinovici
authors.forename: G
authors.initials: G
authors.lastname: Oelsner
authors.forename: L
authors.initials: L
authors.lastname: Freedman
authors.forename: S
authors.initials: S
authors.lastname: Mashiach
authors.forename: B
authors.initials: B
authors.lastname: Lunenfeld
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology; D002996:Clomiphene / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000453:epidemiology; D004967:Estrogens / Q000378:metabolism; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005833:Genital Neoplasms, Female / Q000453:epidemiology*; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007247:Infertility, Female / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D007557:Israel / Q000453:epidemiology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology; D011374:Progesterone / Q000378:metabolism; D012307:Risk Factors
chemical_list: D004967:Estrogens; D005300:Fertility Agents, Female; D006062:Gonadotropins; D002996:Clomiphene; D011374:Progesterone